Trial Profile
A Phase 1b/2, Open Label, Dose Escalation Study of Margetuximab in Combination With Pembrolizumab in Patients With Relapsed/Refractory Advanced HER2+ Gastroesophageal Junction or Gastric Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Aug 2022
Price :
$35
*
At a glance
- Drugs Margetuximab (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors MacroGenics
- 02 Aug 2021 Status changed from active, no longer recruiting to completed.
- 07 Oct 2020 Planned End Date changed from 1 Sep 2020 to 1 Mar 2021.
- 07 Oct 2020 Planned primary completion date changed from 1 Sep 2020 to 1 Feb 2021.